Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Net Income: 2018-2025

Historic Net Income for Whitehawk Therapeutics (WHWK) over the last 7 years, with Sep 2025 value amounting to -$17.7 million.

  • Whitehawk Therapeutics' Net Income fell 41.06% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 67.25%. This contributed to the annual value of -$63.7 million for FY2024, which is 3.15% up from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Net Income stood at -$17.7 million, which was up 66.47% from -$52.8 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Net Income's 5-year high stood at -$1.5 million during Q2 2021, with a 5-year trough of -$87.1 million in Q3 2021.
  • Over the past 3 years, Whitehawk Therapeutics' median Net Income value was -$16.3 million (recorded in 2023), while the average stood at -$19.2 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 2,911.34% in 2021, then soared by 83.38% in 2022.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' Net Income stood at -$16.0 million in 2021, then rose by 12.99% to -$13.9 million in 2022, then dropped by 16.93% to -$16.3 million in 2023, then decreased by 12.32% to -$18.3 million in 2024, then crashed by 41.06% to -$17.7 million in 2025.
  • Its last three reported values are -$17.7 million in Q3 2025, -$52.8 million for Q2 2025, and -$14.4 million during Q1 2025.